Steatosi, infiammazione e fibrosi: meccanismi patogenetici e interazioni
|
|
|
- Madeline Lewis
- 10 years ago
- Views:
Transcription
1 Steatosi, infiammazione e fibrosi: meccanismi patogenetici e interazioni Fabio Marra Dipartimento di Medicina Sperimentale e Clinica University of Florence, Italy [email protected]
2 Female, 72 years old, caucasian (born 1940) Obesity since young age 1970: diagnosis of type 2 diabetes, initially treated with oral antidiabetic medications, switched to insulin in 1992 due to poor glyco-metabolic control. 1992: Diagnosis of Hypertension, treated with ACE inhibitors and then ARB 1998: Diagnosis of Hypercholesterolemia 2005: Discovery of a cold thyroid nodule (stable on follow-up) Never smoked Never consumed alcohol 2000: diagnosis of hepatic steatosis. ALT and GGT reported to be occasionally elevated but predominantly within normal range The patient has since then occasionally performed abdominal US scans without a definite time interval.
3 January 2012: The patient performs an abdominal US scan because of dull, upper right quadrant, abdominal pain: In the context of an enlarged bright liver possibly due to fatty infiltration, there is a large mass (approximately 10cm) constituted by confluent nodules, localized in the VIII, VII, VI segments. No spleen enlargement. No ascites. Evaluated in a different Unit in the hypothesis of hepatic metastases: Normal CEA, CA 19.9, Ca125, CA72.4 Upper GI endoscopy: no alterations, specifically no signs of portal hypertension Colonoscopy: diverticulosis of sigmoid colon. CT scan: no alterations of pancreas Referred to our Unit for further testing
4 US-guided biopsy of hepatic nodule: trabecular hepatocellular carcinoma NASH-related fibrosis without cirrhosis
5 SIMPLE STEATOSIS INSULIN RESISTANCE STEATOHEPATITIS CIRRHOSIS Hepatic decompensation HEPATOCELLULAR CARCINOMA DEATH
6 Pathogenesis of fatty liver Marra & Lotersztajn, Curr Pharm Des 2013
7 SIMPLE STEATOSIS STEATOHEPATITIS Pathology-based definition Hepatocellular damage (ballooning) Inflammation Fibrosis CIRRHOSIS Hepatic decompensation HEPATOCELLULAR CARCINOMA DEATH
8 Definition of lipotoxicity Steatosis A condition whereby fat accumulation results toxic effects on the cell and causes damage or death Steatosis and damage (steatohepatitis) LIPOTOXICITY Fatty acids
9 INSULIN RESISTANCE HEPATIC FATTY ACID OVERLOAD LIPOTOXICITY bad storers STEATOHEPATITIS? TG ACCUMULATION good storers SIMPLE STEATOSIS CIRRHOSIS Hepatic decompensation HEPATOCELLULAR CARCINOMA DEATH
10 FFA Adipokine imbalance Inflammatory cytokines Bacterial products Specific nutrients KC IC TNF IL-1β CCL2 TGF-β ROS JNK NF-κB ER stress Hep HSC Fibrosis
11 Fibrosis Steatosis Hepatic stellate cell activation Apoptosis & ER stress Oxidative stress Inflammation Autophagy Steatosis and damage) (LIPOTOXICITY) Nuclear receptors Cannabinoids
12 ER stress and apoptosis Malhi & Kaufman J Hepatol 2011;54:795
13 Fibrosis Steatosis Hepatic stellate cell activation Apoptosis & ER stress Oxidative stress Inflammation Autophagy Steatosis and damage) (LIPOTOXICITY) Nuclear receptors Cannabinoids
14
15 HSC as targets of oxidative stress-related products Direct effect Cross-talk with cytokine signaling Formation of adducts ROS Cytotoxic effects HNE Collagen TIMPs MCP-1 MMP-2 Migration Proliferation Collagen TIMP-1 MCP-1 Parola et al. BBRC 1996;222:261 Svegliati Baroni et al., Hepatology 1998 Parola et al., J Clin Invest 1999;102:1942 Nieto et al., J Biol Chem 2002; 277:9853
16 Fibrosis Steatosis Hepatic stellate cell activation Apoptosis & ER stress Oxidative stress Inflammation Autophagy Steatosis and damage) (LIPOTOXICITY) Nuclear receptors Cannabinoids
17 Initial biopsy inflammation grade predicts progression to advanced fibrosis Argo et al., J Hepatol 2009; 51:371
18 Pink Floyd, 1975
19 Marra & Lotersztajn, Curr Pharm Des 2013
20 The inflammasomes Schroder & Tschopp Cell 2010;140, 821
21 The concept of sterile inflammation Kubes & Mehal, Grastroenterology 2012
22 The inflammasome pathway is activated in the MCD model of NASH Csak et al., Hepatology 2011;54:133
23 Inflammasome deficiency protects from insulin resistance and steatosis Stienstra et al., PNAS 2011;108:15324
24 Inflammasome deficiency worsens NASH interacting with the microbiome Henao-Mejia et al., Nature 2012; 482:179
25 Fibrosis Steatosis Hepatic stellate cell activation Apoptosis & ER stress Oxidative stress Inflammation Autophagy Steatosis and damage) (LIPOTOXICITY) Nuclear receptors Cannabinoids
26 Autophagy: a new player in liver diseases Amir and Czaja, Expert Rev Gastroneterol Hepatol 2011
27 Fibrosis Steatosis Hepatic stellate cell activation Apoptosis & ER stress Oxidative stress Inflammation Autophagy Steatosis and damage) (LIPOTOXICITY) Nuclear receptors Cannabinoids
28 The dual PPARα/δ agonist GFT505 in models of NAFLD/NASH Staels et al., Hepatology 2013
29 The Farnesoid X Receptor Agonist Obeticholic Acid in NAFLD Mudaliar et al., Gastroenterology 2013
30 Fibrosis Steatosis Hepatic stellate cell activation Apoptosis & ER stress Oxidative stress Inflammation Autophagy Steatosis and damage) (LIPOTOXICITY) Nuclear receptors Cannabinoids
31 Patti. J Clin Invest. 2010;120:2646
32 FFA Adipokine imbalance Inflammatory cytokines Bacterial products Specific nutrients KC IC TNF IL-1β CCL2 TGF-β ROS JNK NF-κB ER stress Hep HSC Fibrosis
33 iron copper Saturated FA Lipotoxicity ROS Inflammation LPS Fructose Steatosis AGE n-3 PUFA Cholesterol Marra & Lotersztajn, Curr Pharm Des 2013
34 Singh, Cell 2007;130:765
35 Effecs of curcumin on Fibrogenesis PPAR-γ Oxidative stress
36 Inflammasome activation Berberine Kubes& Mehal, Grastroenterology 2012
37 FFA Adipokine imbalance Inflammatory cytokines Bacterial products Specific nutrients KC IC TNF IL-1β CCL2 TGF-β ROS JNK NF-κB ER stress Hep HSC Fibrosis
38 Inflammation and immunity in obesity Lumeng, JCI 2011
39 Adipose tissue changes after weight gain FFA Treg TNF-α IL-1β CCL2 OPN inos Adipose tissue IR Lipolysis M1 Leptin Adiponectin CCL2 M1 M2 Weight gain M2 Treg Apoptosis Hypoxia Lean Obese Marra & Lotersztajn, Curr Pharm Des 2013
40 Marra & Bertolani, Hepatology 2009;50:957
41 Myostatin HSC TGF-beta-like effects: Autoinduction of TGF-beta TIMP-1 Collagen Growth arrest Smad3 phosphorylation Chemotaxis
42 Zimmer & Lammert, Best Pract Res Clin Gastroenterol 2011
43
44
45
NASH: It is not JUST a Fatty Liver. Karen F. Murray, M.D. Director of Hepatobiliary Program Children s Hospital and Regional Medical Center
NASH: It is not JUST a Fatty Liver Karen F. Murray, M.D. Director of Hepatobiliary Program Children s Hospital and Regional Medical Center Stages of Fatty Liver Disorders Fatty Liver 16-35% of Western
THE ENDOCANNABINOID SYSTEM AS A THERAPEUTIC TARGET FOR LIVER DISEASES. Key Points
December 2008 (Vol. 1, Issue 3, pages 36-40) THE ENDOCANNABINOID SYSTEM AS A THERAPEUTIC TARGET FOR LIVER DISEASES By Sophie Lotersztajn, PhD, Ariane Mallat, MD, PhD Inserm U841, Hôpital Henri Mondor,
Non Alcoholic Steato-Hepatitis (NASH)
Non Alcoholic Steato-Hepatitis (NASH) DISCLAIMER NEITHER THE PUBLISHER NOR THE AUTHORS ASSUME ANY LIABILITY FOR ANY INJURY AND OR DAMAGE TO PERSONS OR PROPERTY ARISING FROM THIS WEBSITE AND ITS CONTENT.
Non-alcoholic fatty liver disease: Prognosis and Treatment
Non-alcoholic fatty liver disease: Prognosis and Treatment Zachary Henry, M.D. Assistant Professor UVA Gastroenterology & Hepatology October 28, 2015 Overview Case Presentation Prognosis Effects of fibrosis
Non-alcoholic Fatty Liver Disease (NAFLD): Does Anything Help?
Non-alcoholic Fatty Liver Disease (NAFLD): Does Anything Stephen Caldwell, MD Director of Hepatology University of Virginia Case: 36 yo F, T2 DM, abn liver enzymes, mother died of cryptogenic cirrhosis
Intracellular fat deposition
Who Gets Alcoholic Liver Disease? Chris Day Newcastle University Alcoholic Fatty Liver (Steatosis) Fatty hepatocytes Intracellular fat deposition Alcoholic SteatoHepatitis (ASH) Fat deposits Inflammation
BACKGROUND MEDIA INFORMATION Fast facts about liver disease
BACKGROUND MEDIA INFORMATION Fast facts about liver disease Liver, or hepatic, disease comprises a wide range of complex conditions that affect the liver. Liver diseases are extremely costly in terms of
SHAHID AZIZ DO, FACOI.
SHAHID AZIZ DO, FACOI. ASSOCIATE CLINICAL PROFESSOR OF GI AND LIVER DISEASE. UT SOUTHWESTERN HEALTH SCIENCE CENTER, DALLAS ADJUNCT CLINICAL ASSISTANT PROFESSOR DEPT OF MEDICINE UNT HEALTH SCIENCE CENTER
Your Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007
Your Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007 The cardiometabolic risk syndrome is increasingly recognized
GT-020 Phase 1 Clinical Trial: Results of Second Cohort
GT-020 Phase 1 Clinical Trial: Results of Second Cohort July 29, 2014 NASDAQ: GALT www.galectintherapeutics.com 2014 Galectin Therapeutics inc. Forward-Looking Statement This presentation contains, in
Body Composition & Longevity. Ohan Karatoprak, MD, AAFP Clinical Assistant Professor, UMDNJ
Body Composition & Longevity Ohan Karatoprak, MD, AAFP Clinical Assistant Professor, UMDNJ LONGEVITY Genetic 25% Environmental Lifestyle Stress 75% BMI >30 OBESE 25-30 OVERWEIGHT 18-25 NORMAL WEIGHT 18
Role of Body Weight Reduction in Obesity-Associated Co-Morbidities
Obesity Role of Body Weight Reduction in JMAJ 48(1): 47 1, 2 Hideaki BUJO Professor, Department of Genome Research and Clinical Application (M6) Graduate School of Medicine, Chiba University Abstract:
Boehringer Ingelheim- sponsored Satellite Symposium. HCV Beyond the Liver
Boehringer Ingelheim- sponsored Satellite Symposium HCV Beyond the Liver HCV AS A METABOLIC MODIFIER: STEATOSIS AND INSULIN RESISTANCE Francesco Negro University Hospital of Geneva Switzerland Clinical
Give a NOD to diabetes:
Give a NOD to diabetes: NOD proteins ti link immunity it and metabolism tbli Jonathan Schertzer McMaster University McMaster University Faculty of Health Sciences Department of Biochemistry and Biomedical
Review: How to work up your patient with Hepatitis C
Review: How to work up your patient with Hepatitis C You screened your patient, and now the HCV antibody test is positive. What do you do next? The antibody test only means they have been exposed to HCV.
Subproject 4: Specification and Documentation of Metabolic and Neoplastic Diseases
Subproject 4: Specification and Documentation of Metabolic and Neoplastic Diseases M. Trauner, Division of Gastroenterology and Hepatology, Department of Internal Medicine, MUG Co- Investigator: H. Samonigg,
1. PATHOPHYSIOLOGY OF METABOLIC SYNDROME
1. PATHOPHYSIOLOGY OF METABOLIC SYNDROME Izet Aganović, Tina Dušek Department of Internal Medicine, Division of Endocrinology, University Hospital Center Zagreb, Croatia 1 Introduction The metabolic syndrome
What to Do with the Patient With Abnormal Liver Enzymes? Nizar N. Zein, M.D. The Cleveland Clinic
What to Do with the Patient With Abnormal Liver Enzymes? Nizar N. Zein, M.D. The Cleveland Clinic Introduction Elevated liver enzymes is often not a clinical problem by itself. However it is a warning
MANAGEMENT OF LIVER CIRRHOSIS
MANAGEMENT OF LIVER CIRRHOSIS Information Leaflet Your Health. Our Priority. Page 2 of 6 What is cirrhosis? Cirrhosis is a result of long-term, continuous damage to the liver and may be due to many different
Two Cases of Non-Alcoholic Steato-Hepatitis Developing from Simple Fatty Liver
case series Two Cases of Non-Alcoholic Steato-Hepatitis Developing from Simple Fatty Liver Soo Ryang Kim, Taisuke Nakajima, Kenji Ando, Keiji Mita, Katsumi Fukuda Department of Gastroenterology, Kobe Asahi
Alanine aminotransferase (serum, plasma)
Alanine aminotransferase (serum, plasma) 1 Name and description of analyte 1.1 Name of analyte Alanine aminotransferase (ALT) 1.2 Alternative names Systematic name L alanine:2 oxoglutarate aminotransferase
Abnormal Liver Function. Dr William Alazawi MA(Cantab) PhD MRCP Senior Lecturer and Consultant in Hepatology Queen Mary, University of London
Abnormal Liver Function Dr William Alazawi MA(Cantab) PhD MRCP Senior Lecturer and Consultant in Hepatology Queen Mary, University of London Does Liver Disease Matter? Mortality in England & Wales Liver-related
Primary Care Guidance Program: Non-Alcohol related Fatty Liver Disease (NAFLD) Guidance on Management in Primary Care
Primary Care Guidance Program: Non-Alcohol related Fatty Liver Disease (NAFLD) Guidance on Management in Primary Care This advice has been developed to help GPs with shared care of patients with Non- Alcohol
Liver Transplantation for Hepatocellular Carcinoma. John P. Roberts, MD Chief, Division of Transplant Service University of California, San Francisco
Liver Transplantation for Hepatocellular Carcinoma John P. Roberts, MD Chief, Division of Transplant Service University of California, San Francisco Hepatocellular Carcinoma HCC is the 5th most common
Introduction. Pathogenesis of type 2 diabetes
Introduction Type 2 diabetes mellitus (t2dm) is the most prevalent form of diabetes worldwide. It is characterised by high fasting and high postprandial blood glucose concentrations (hyperglycemia). Chronic
Non-Alcoholic Fatty Liver Disease
Non-Alcoholic Fatty Liver Disease Information for patients and families UHN Read this information to learn: what non-alcoholic fatty liver disease is what causes it how it s treated how to prevent it where
New Approaches to Treating Fatty Liver Disease. Mack C. Mitchell, MD University of Texas Southwestern Medical Center Dallas, Texas
New Approaches to Treating Fatty Liver Disease Mack C. Mitchell, MD University of Texas Southwestern Medical Center Dallas, Texas Disclosures Stockholder: Bristol-Myers Squibb, Medtronic, Novartis, Pfizer
NUTRITION IN LIVER DISEASES
NUTRITION IN LIVER DISEASES 1. HEPATITIS: Definition: - Viral inflammation of liver cells. Types: a. HAV& HEV, transmitted by fecal-oral route. b. HBV & HCV, transmitted by blood and body fluids. c. HDV
Brochure More information from http://www.researchandmarkets.com/reports/3503782/
Brochure More information from http://www.researchandmarkets.com/reports/3503782/ Non-Alcoholic SteatoHepatitis (NASH): An Analysis of Disease Prevalence, Drugs in Development, Regulatory Guidelines and
Diabetes and Obesity. The diabesity epidemic
Diabetes and Obesity Frank B. Diamond, Jr. M.D. Professor of Pediatrics University of South Florida College of Medicine The diabesity epidemic Prevalence of diabetes worldwide was over 135 million people
LIVER CANCER AND TUMOURS
LIVER CANCER AND TUMOURS LIVER CANCER AND TUMOURS Healthy Liver Cirrhotic Liver Tumour What causes liver cancer? Many factors may play a role in the development of cancer. Because the liver filters blood
NAFLD/NASH: Criteri diagnostici e prognostici
Monotematica AISF Personalizzazione della Cura in Epatologia NAFLD/NASH: Criteri diagnostici e prognostici Pisa 17-19 ottobre 2013 Elisabetta Bugianesi MD, PhD Division of Gastro-Hepatology, University
Type 2 Diabetes and Prediabetes: A New Understanding of Cause and Treatment. Bruce Latham, M.D. Endocrine Specialists Greenville Health System
Type 2 Diabetes and Prediabetes: A New Understanding of Cause and Treatment Bruce Latham, M.D. Endocrine Specialists Greenville Health System Objectives for this presentation - Understand the thrifty genotype
Liver, Gallbladder, Exocrine Pancreas KNH 406
Liver, Gallbladder, Exocrine Pancreas KNH 406 2007 Thomson - Wadsworth LIVER Anatomy - functions With disease blood flow becomes obstructed Bile All bile drains into common hepatic duct Liver Bile complex
Evaluation and Prognosis of Patients with Cirrhosis
Evaluation and Prognosis of Patients with Cirrhosis Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded
Molecular Mechanisms and New Treatment Strategies for Non-Alcoholic Steatohepatitis (NASH)
Int. J. Mol. Sci. 2014, 15, 7352-7379; doi:10.3390/ijms15057352 Review OPEN ACCESS International Journal of Molecular Sciences ISSN 1422-0067 www.mdpi.com/journal/ijms Molecular Mechanisms and New Treatment
Non Alcoholic Fatty Liver Disease
Linköping University Medical Dissertations No. 1081 Non Alcoholic Fatty Liver Disease A clinical and histopathological study Mattias Ekstedt Division of Gastroenterology and Hepatology Department of Clinical
NP/PA Clinical Hepatology Fellowship Summary of Year-Long Curriculum
OVERVIEW OF THE FELLOWSHIP The goal of the AASLD NP/PA Fellowship is to provide a 1-year postgraduate hepatology training program for nurse practitioners and physician assistants in a clinical outpatient
2.1 AST can be measured in heparin plasma or serum. 3 Summary of clinical applications and limitations of measurements
Aspartate aminotransferase (serum, plasma) 1 Name and description of analyte 1.1 Name of analyte Aspartate aminotransferase (AST) 1.2 Alternative names Systematic name L aspartate:2 oxoglutarate aminotransferase
LA TERAPIA PER HBV ed HCV Differenze di Genere? Alfredo Alberti. Dipartimento di Medicina Molecolare UOC Medicina Generale VIMM Università di Padova
LA TERAPIA PER HBV ed HCV Differenze di Genere? Alfredo Alberti Dipartimento di Medicina Molecolare UOC Medicina Generale VIMM Università di Padova HBV ed HCV Due virus Diversi ma con molte Cose in Comune
After the Cure: Long-Term Management of HCV Liver Disease Norah A. Terrault, MD, MPH
After the Cure: Long-Term Management of HCV Liver Disease Norah A. Terrault, MD, MPH Professor of Medicine Department of Gastroenterology Director, Viral Hepatitis Center University of California San Francisco
Isagenix Clinical Research Summary Suk Cho, Ph.D., Eric Gumpricht, Ph.D., David Despain, M.Sc.
Isagenix Clinical Research Summary Suk Cho, Ph.D., Eric Gumpricht, Ph.D., David Despain, M.Sc. UIC study finds subjects on Isagenix products lost more body fat, lost more visceral fat, showed greater adherence,
ALPHA (TNFa) IN OBESITY
THE ROLE OF TUMOUR NECROSIS FACTOR ALPHA (TNFa) IN OBESITY Alison Mary Morris, B.Sc (Hons) A thesis submitted to Adelaide University for the degree of Doctor of Philosophy Department of Physiology Adelaide
Nonalcoholic Fatty Liver Disease. Dietary and Lifestyle Guidelines
Nonalcoholic Fatty Liver Disease Dietary and Lifestyle Guidelines Risk factors for NAFLD Typically, but not always seen in patients who are overweight. May have Diabetes and or insulin resistance high
New Approaches to a Major Public-Health Problem Infectious Diseases. Ethan Weiner, M.D. Senior Vice President Therapeutic Area Development Head
New Approaches to a Major Public-Health Problem Infectious Diseases Ethan Weiner, M.D. Senior Vice President Therapeutic Area Development Head Overview The Burden Of Infectious Disease Is Large And May
NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IN MEN WITH TYPE 2 DIABETES
NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IN MEN WITH TYPE 2 DIABETES D. Bakalov 1, M. Boyanov 1, G. Sheinkova 1, L. Vezenkova 1, G. Prodanova 2, V. Christov 1 1 Endocrinology Clinic 2 Sonography unit
4/4/2013. Mike Rizo, Pharm D, MBA, ABAAHP THE PHARMACIST OF THE FUTURE? METABOLIC SYNDROME AN INTEGRATIVE APPROACH
METABOLIC SYNDROME AN INTEGRATIVE APPROACH AN OPPORTUNITY FOR PHARMACISTS TO MAKE A DIFFERENCE Mike Rizo, Pharm D, MBA, ABAAHP THE EVOLUTION OF THE PHARMACIST 1920s 1960s 2000s THE PHARMACIST OF THE FUTURE?
THE NEW INTERCEPT STRATEGY FOR OCA AND THE IMPACT OF GENFIT- GFT505 MARKET
THE NEW INTERCEPT STRATEGY FOR OCA AND THE IMPACT OF GENFIT- GFT505 MARKET (G DIVRY- March the 22th, 2015) The new strategy of Intercept for OCA seems to be revealed in their communication last Friday
Which drugs should be used to treat diabetes in cirrhotic patients?
Which drugs should be used to treat diabetes in cirrhotic patients? Frankfurt am Main 10-12 September 2015 Jörg Bojunga Medizinische Klinik I Johann Wolfgang Goethe-Universität Frankfurt am Main Significance
Liver, Gallbladder and Pancreas diseases. Premed 2 Pathophysiology
Liver, Gallbladder and Pancreas diseases Premed 2 Pathophysiology Pancreas Pancreatitis Acute Pancreatitis Autodigestion of the pancreas due to activation of the enzymes Hemorrhagic fat necrosis, calcium
The State of the Liver in the Adult Patient after Fontan Palliation
The State of the Liver in the Adult Patient after Fontan Palliation Fred Wu, M.D. Boston Adult Congenital Heart Service Boston Children s Hospital/Brigham & Women s Hospital 7 th National Adult Congenital
Subject Index. Bariatric surgery, obesity management 134
Subject Index Acromegaly, PCOS differential diagnosis 149, 150, 154, 155 Adipokines, see specific adipokines Adiponectin, metabolic syndrome role 41 43 Adolescents, PCOS diagnosis 16, 17 Adrenal hyperplasia,
Surveillance for Hepatocellular Carcinoma
Surveillance for Hepatocellular Carcinoma Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded on April
Gastrointestinal Bleeding
Gastrointestinal Bleeding Introduction Gastrointestinal bleeding is a symptom of many diseases rather than a disease itself. A number of different conditions can cause gastrointestinal bleeding. Some causes
Men Sexual Dysfunction Associated with Obesity and Metabolic Syndrome
Men Sexual Dysfunction Associated with Obesity and Metabolic Syndrome By Aly A. Abbassy, MD, FACE Professor of Medicine (Endocrinology) Alexandria University My Talk will include: 1-Types of Men sexual
Patterns of abnormal LFTs and their differential diagnosis
Patterns of abnormal LFTs and their differential diagnosis Professor Matthew Cramp South West Liver Unit and Peninsula Schools of Medicine and Dentistry, Plymouth Summary liver function / liver function
Cardiovascular Disease Risk Factors Part XII Insulin Resistance By James L. Holly, MD Your Life Your Health The Examiner September 15, 2005
Cardiovascular Disease Risk Factors Part XII By James L. Holly, MD Your Life Your Health The Examiner September 15, 2005 As we approach the end of our extended series on cardiovascular disease risk factors,
Antioxidant response in patients with chronic hepatitis B or C.
Antioxidant response in patients with chronic hepatitis B or C. Kamila Wójcik, Anna Piekarska, Elżbieta Jabłonowska Department of Infectious Diseases and Hepatology, Medical University of Lodz, Poland
Transmission of HCV in the United States (CDC estimate)
Transmission of HCV in the United States (CDC estimate) Past and Future US Incidence and Prevalence of HCV Infection Decline among IDUs Overall incidence Overall prevalence Infected 20+ years Armstrong
Rheumatoid Arthritis. Treating Inflammation. Sequoia Education Systems, Inc http://www.functionalmedicineuniversity.com 1. How is RA Diagnosed?
Rheumatoid Arthritis Causes, Assessment and Treatment How is RA Diagnosed? The following labs make up the basics of ruling in or out RA. Citrullinated Peptide (anti-ccp) Antibodies Rheumatoid factor Erythrocyte
Fat: A matter of disturbance for the immune system
Online Submissions: http://www.wjgnet.com/1007-9327office [email protected] doi:10.3748/wjg.v16.i38.4762 World J Gastroenterol 2010 October 14; 16(38): 4762-4772 ISSN 1007-9327 (print) ISSN 2219-2840 (online)
Sovaldi (sofosbuvir) Prior Authorization Criteria
INITIAL REVIEW CRITERIA Sovaldi (sofosbuvir) Prior Authorization Criteria 1. Adult patient age 18 years old; AND 2. Prescribed by a hepatologist, gastroenterologist, infectious disease specialist, transplant
Indications in Hepatology and Liver Diseases
exclusively working in Health Care sananet GmbH Tilo Stolzke Breite Str. 6-8 23562 Lübeck Germany Telefon : +49 451 400 8301 Telefax : +49 451 400 8302 E-Mail : [email protected] Internet : www.sananet.com
Early Colonoscopy in Patients with Acute Diverticulitis Simon Bar-Meir, M.D.
Early Colonoscopy in Patients with Acute Diverticulitis Simon Bar-Meir, M.D. Professor of Medicine Germanis Kaufman Chair of Gastroenterology Director, Dept. of Gastroenterology Chaim Sheba Medical Center,
Update on Hepatitis C. Sally Williams MD
Update on Hepatitis C Sally Williams MD Hep C is Everywhere! Hepatitis C Magnitude of the Infection Probably 8 to 10 million people in the U.S. are infected with Hep C 30,000 new cases are diagnosed annually;
CMS Limitations Guide - Laboratory Services
CMS Limitations Guide - Laboratory Services Starting October 1, 2015, CMS will update their exisiting medical necessity limitations on tests and procedures to correspond to ICD-10 codes. This limitattions
Diabetes mellitus. Lecture Outline
Diabetes mellitus Lecture Outline I. Diagnosis II. Epidemiology III. Causes of diabetes IV. Health Problems and Diabetes V. Treating Diabetes VI. Physical activity and diabetes 1 Diabetes Disorder characterized
Non-Alcoholic Fatty Liver Disease: A Patient s Guide
U.S. Department of Veterans Affairs Veterans Health Administration Office of Public Health Non-Alcoholic Fatty Liver Disease: A Patient s Guide National Institute of Diabetes and Digestive and Kidney Diseases,
Hepatitis C treatment What to expect.
Hepatitis C treatment What to expect. Anne Glass Hepatitis Clinical Nurse Consultant Liver Clinic SSWAHS Bankstown and Liverpool Hospital Contact 87384074 Monday -Friday What s hepatitis? Hepatitis means
The degree of liver inflammation or damage (grade) Presence and extent of fatty liver or other metabolic liver diseases
ilearning about your health Liver Biopsy www.cpmc.org/learning What is a Liver Biopsy? A liver biopsy is a procedure where a specially trained doctor (typically a hepatologist, radiologist, or gastroenterologist)
EVALUATION OF LIVER FIBROSIS BY FIBROSCAN
EVALUATION OF LIVER FIBROSIS BY FIBROSCAN M. Beaugrand Service d Hépatologied Hopital J. Verdier BONDY 93143 et Université Paris XIII DRESDEN 13.10.2007 ASSESSMENT OF FIBROSIS : WHY? Management of individual
LIVER FUNCTION TESTS AND STATINS
LIVER FUNCTION TESTS AND STATINS Philippe J. Zamor and Mark W. Russo Current Opinion in Cardiology 2011,26:338 341 SUMMARY Purpose of review: To discuss recent data on statins in patients with elevated
SDS gel electrophoresis was performed using a 4% by 20% gradient gel 8. Quantification of Western blots was performed using Image J Processing and
Supplemental Material: Western blot: SDS gel electrophoresis was performed using a 4% by 20% gradient gel 8. Quantification of Western blots was performed using Image J Processing and Analysis (NIH). Quantitative
New IDSA/AASLD Guidelines for Hepatitis C
NORTHWEST AIDS EDUCATION AND TRAINING CENTER New IDSA/AASLD Guidelines for Hepatitis C John Scott, MD, MSc Associate Professor, UW SoM Asst Director, Liver Clinic, Harborview Medical Center Presentation
HEPATOCELLULAR CARCINOMA (HCC) RESECTION VERSUS TRANSPLANTATION. Francis Yao, M.D.
UCSF TRANSPLANT CONFERENCE - 9/28/2012 HEPATOCELLULAR CARCINOMA (HCC) RESECTION VERSUS TRANSPLANTATION Francis Yao, M.D. Professor of Clinical Medicine and Surgery Medical Director, Liver Transplantation
Amylase and Lipase Tests
Amylase and Lipase Tests Also known as: Amy Formal name: Amylase Related tests: Lipase The Test The blood amylase test is ordered, often along with a lipase test, to help diagnose and monitor acute or
Non-alcoholic Fatty Liver Disease, as a Possible Independent Risk Factor for Obliterative Arteriopathy
RESEARCH ARTICLE Acta Medica Marisiensis 2012;58(5):341-345 Non-alcoholic Fatty Liver Disease, as a Possible Independent Risk Factor for Obliterative Arteriopathy Szalman Krisztina Borbála, Puskás A 2
Cirrhosis and HCV. Jonathan Israel M.D.
Cirrhosis and HCV Jonathan Israel M.D. Outline Relationship of fibrosis and cirrhosisprevalence and epidemiology. Sequelae of cirrhosis Diagnosis of cirrhosis Effect of cirrhosis on efficacy of treatment
Cirrhosis and HCC. Dr.Abonyi Margit PhD SE 1st.Medical Clinic
Cirrhosis and HCC Dr.Abonyi Margit PhD SE 1st.Medical Clinic 2011 1 Cirrhosis 6.000-8.000 deaths in Hungary A 4. cause of death in Hungary Kb. 1.000.000 suffering of chronic hepatic problem M:F 2:1 5-20
